Cargando…

Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report

RATIONALE: Antibiotic resistance poses a challenge for Helicobacter pylori eradication treatment. Current guidelines strongly recommend avoiding repeated treatments with the same antibiotic to prevent the emergence of drug resistance. However, for penicillin-allergic patients with recurrent H. pylor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Siya, Chen, Han, Huang, Keting, Jin, Duochen, Zhang, Guoxin, Ye, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969298/
https://www.ncbi.nlm.nih.gov/pubmed/33725850
http://dx.doi.org/10.1097/MD.0000000000024915
_version_ 1783666216138702848
author Kong, Siya
Chen, Han
Huang, Keting
Jin, Duochen
Zhang, Guoxin
Ye, Feng
author_facet Kong, Siya
Chen, Han
Huang, Keting
Jin, Duochen
Zhang, Guoxin
Ye, Feng
author_sort Kong, Siya
collection PubMed
description RATIONALE: Antibiotic resistance poses a challenge for Helicobacter pylori eradication treatment. Current guidelines strongly recommend avoiding repeated treatments with the same antibiotic to prevent the emergence of drug resistance. However, for penicillin-allergic patients with recurrent H. pylori eradication failures, avoiding repeated treatments with the same antibiotic severely limits the choice of treatment. PATIENT CONCERNS: A 47-year-old woman with a penicillin allergy for whom 2 previous levofloxacin and bismuth-based therapies had failed. DIAGNOSIS: H. pylori infection. INTERVENTIONS: Agar dilution susceptibility testing and gene sequence analysis was performed to confirm levofloxacin susceptibility again. Therefore, we treated her with a 14-day regimen consisting of levofloxacin (500 mg once daily), furazolidone (100 mg twice daily), colloidal bismuth pectin (220 mg twice daily), and esomeprazole (20 mg twice daily). OUTCOMES: The patient was successfully treated with a third levofloxacin and bismuth-based regimen. LESSONS: Antibiotics included in previous failed therapies need not be eliminated if no antibiotic resistance is found on antimicrobial susceptibility testing.
format Online
Article
Text
id pubmed-7969298
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-79692982021-03-18 Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report Kong, Siya Chen, Han Huang, Keting Jin, Duochen Zhang, Guoxin Ye, Feng Medicine (Baltimore) 4500 RATIONALE: Antibiotic resistance poses a challenge for Helicobacter pylori eradication treatment. Current guidelines strongly recommend avoiding repeated treatments with the same antibiotic to prevent the emergence of drug resistance. However, for penicillin-allergic patients with recurrent H. pylori eradication failures, avoiding repeated treatments with the same antibiotic severely limits the choice of treatment. PATIENT CONCERNS: A 47-year-old woman with a penicillin allergy for whom 2 previous levofloxacin and bismuth-based therapies had failed. DIAGNOSIS: H. pylori infection. INTERVENTIONS: Agar dilution susceptibility testing and gene sequence analysis was performed to confirm levofloxacin susceptibility again. Therefore, we treated her with a 14-day regimen consisting of levofloxacin (500 mg once daily), furazolidone (100 mg twice daily), colloidal bismuth pectin (220 mg twice daily), and esomeprazole (20 mg twice daily). OUTCOMES: The patient was successfully treated with a third levofloxacin and bismuth-based regimen. LESSONS: Antibiotics included in previous failed therapies need not be eliminated if no antibiotic resistance is found on antimicrobial susceptibility testing. Lippincott Williams & Wilkins 2021-03-12 /pmc/articles/PMC7969298/ /pubmed/33725850 http://dx.doi.org/10.1097/MD.0000000000024915 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 4500
Kong, Siya
Chen, Han
Huang, Keting
Jin, Duochen
Zhang, Guoxin
Ye, Feng
Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report
title Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report
title_full Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report
title_fullStr Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report
title_full_unstemmed Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report
title_short Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report
title_sort antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for helicobacter pylori infection: a case report
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969298/
https://www.ncbi.nlm.nih.gov/pubmed/33725850
http://dx.doi.org/10.1097/MD.0000000000024915
work_keys_str_mv AT kongsiya antibioticsusceptibilityguidedreuseoflevofloxacinbasedtherapyinapenicillinallergicpatientforhelicobacterpyloriinfectionacasereport
AT chenhan antibioticsusceptibilityguidedreuseoflevofloxacinbasedtherapyinapenicillinallergicpatientforhelicobacterpyloriinfectionacasereport
AT huangketing antibioticsusceptibilityguidedreuseoflevofloxacinbasedtherapyinapenicillinallergicpatientforhelicobacterpyloriinfectionacasereport
AT jinduochen antibioticsusceptibilityguidedreuseoflevofloxacinbasedtherapyinapenicillinallergicpatientforhelicobacterpyloriinfectionacasereport
AT zhangguoxin antibioticsusceptibilityguidedreuseoflevofloxacinbasedtherapyinapenicillinallergicpatientforhelicobacterpyloriinfectionacasereport
AT yefeng antibioticsusceptibilityguidedreuseoflevofloxacinbasedtherapyinapenicillinallergicpatientforhelicobacterpyloriinfectionacasereport